The US Food and Drug Administration FDA released a notice to the public on the results that came after conducting a clinical trial for Eisai’s weight management drug Belviq (lorcaserin), a weight-loss drug, claiming that it possesses potential risks leading to cancer. The FDA has also issued a warning regarding the extended released version of the same drug.

The FDA further added, “At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk. However, we wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review”.